WDNA vs. CNCR

Last updated Jul 14, 2026

WDNA (WisdomTree BioRevolution Fund) and CNCR (Loncar Cancer Immunotherapy ETF) are both Health & Biotech Equities funds - WDNA tracks the WisdomTree BioRevolution Index while CNCR tracks the Loncar Cancer Immunotherapy Index. Both are passively managed. WDNA charges 0.45%/yr vs 0.79%/yr for CNCR.

Performance

WDNA vs. CNCR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in WisdomTree BioRevolution Fund (WDNA) and Loncar Cancer Immunotherapy ETF (CNCR). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

WDNA

• 1D: -1.12%
• 1M: 12.55%
• 6M: 14.81%
• YTD: 20.12%
• 1Y: 48.13%
• 3Y*: 6.33%
• 5Y*: -3.07%
• 10Y*: —

CNCR

• 1D: 0.00%
• 1M: 0.00%
• 6M: —
• YTD: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

WDNA vs. CNCR - Yearly Performance Comparison

	2026 (YTD)
WDNA WisdomTree BioRevolution Fund	17.39%
CNCR Loncar Cancer Immunotherapy ETF	0.00%

WDNA vs. CNCR - Sectors Allocation Comparison

Sectors	WDNA	CNCR
Healthcare	85.0%	96.6%
Basic Materials	6.5%	-
Consumer Defensive	3.0%	-
Energy	1.1%	-
Communication Services	-	-
Consumer Cyclical	-	-
Financial Services	-	3.3%
Industrials	-	-
Real Estate	-	-
Technology	-	-
Utilities	-	-

Return for Risk

WDNA vs. CNCR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

WDNA

WDNA Risk / Return Rank: 73
WDNA Sharpe Ratio Rank: 74
WDNA Sortino Ratio Rank: 74
WDNA Omega Ratio Rank: 64
WDNA Calmar Ratio Rank: 88
WDNA Martin Ratio Rank: 66

CNCR

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

WDNA vs. CNCR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for WisdomTree BioRevolution Fund (WDNA) and Loncar Cancer Immunotherapy ETF (CNCR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	WDNA	CNCR	Difference
Sharpe ratio: Return per unit of total volatility	1.87	—	—
Sortino ratio: Return per unit of downside risk	2.66	—	—
Omega ratio: Gain probability vs. loss probability	1.31	—	—
Calmar ratio: Return relative to maximum drawdown	4.14	—	—
Martin ratio: Return relative to average drawdown	9.29	—	—

Drawdowns

WDNA vs. CNCR - Drawdown Comparison

The maximum WDNA drawdown since its inception was -58.87%, which is greater than CNCR's maximum drawdown of 0.00%. Use the drawdown chart below to compare losses from any high point for WDNA and CNCR.

Drawdown Indicators

	WDNA	CNCR	Difference
Max Drawdown Largest peak-to-trough decline	-58.87%	0.00%	-58.87%
Max Drawdown (1Y) Largest decline over 1 year	-11.70%	—	—
Max Drawdown (3Y) Largest decline over 3 years	-38.25%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-58.87%	—	—
Current Drawdown Current decline from peak	-22.68%	0.00%	-22.68%
Average Drawdown Average peak-to-trough decline	-35.42%	0.00%	-35.42%
Ulcer Index Depth and duration of drawdowns from previous peaks	5.20%	—	—

Volatility

Volatility by Period

	WDNA	CNCR	Difference
Volatility (1M) Calculated over the trailing 1-month period	6.49%	—	—
Volatility (6M) Calculated over the trailing 6-month period	17.22%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	25.90%	0.00%	+25.90%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	25.24%	0.00%	+25.24%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	25.07%	0.00%	+25.07%

WDNA vs. CNCR - Expense Ratio Comparison

WDNA has a 0.45% expense ratio, which is lower than CNCR's 0.79% expense ratio.

Dividends

WDNA vs. CNCR - Dividend Comparison

WDNA's dividend yield for the trailing twelve months is around 3.80%, while CNCR has not paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021
CNCR Loncar Cancer Immunotherapy ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
WDNA WisdomTree BioRevolution Fund	3.80%	4.57%	0.75%	0.80%	0.38%	0.10%

Frequently Asked Questions

Which ETF is better, WDNA or CNCR?

On fees, WDNA is cheaper at 0.45% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, WDNA or CNCR?

WDNA is cheaper with a 0.45% expense ratio, compared with 0.79% for CNCR.

Which ETF pays a higher dividend yield, WDNA or CNCR?

WDNA has the higher dividend yield at 3.80%, compared with 0.00% for CNCR.

What is the main difference between WDNA and CNCR?

WDNA tracks WisdomTree BioRevolution Index, while CNCR tracks Loncar Cancer Immunotherapy Index. They also come from different issuers: WisdomTree and Exchange Traded Concepts. Their fees differ too: 0.45% for WDNA and 0.79% for CNCR.